Keros Therapeutics (KROS) Competitors $58.04 -1.60 (-2.68%) (As of 10/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KROS vs. SRRK, DRNA, SRRA, YMAB, AMRN, ROIV, LEGN, VKTX, ITCI, and RVMDShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Scholar Rock (SRRK), Dicerna Pharmaceuticals (DRNA), Sierra Oncology (SRRA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Roivant Sciences (ROIV), Legend Biotech (LEGN), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector. Keros Therapeutics vs. Scholar Rock Dicerna Pharmaceuticals Sierra Oncology Y-mAbs Therapeutics Amarin Roivant Sciences Legend Biotech Viking Therapeutics Intra-Cellular Therapies Revolution Medicines Scholar Rock (NASDAQ:SRRK) and Keros Therapeutics (NASDAQ:KROS) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability. Do institutionals & insiders have more ownership in SRRK or KROS? 91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 26.2% of Scholar Rock shares are held by insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend SRRK or KROS? Scholar Rock currently has a consensus price target of $33.29, indicating a potential upside of 12.45%. Keros Therapeutics has a consensus price target of $89.11, indicating a potential upside of 52.61%. Given Keros Therapeutics' higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Keros Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SRRK or KROS? In the previous week, Keros Therapeutics had 8 more articles in the media than Scholar Rock. MarketBeat recorded 11 mentions for Keros Therapeutics and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.25 beat Keros Therapeutics' score of 1.01 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer SRRK or KROS? Scholar Rock received 113 more outperform votes than Keros Therapeutics when rated by MarketBeat users. However, 70.15% of users gave Keros Therapeutics an outperform vote while only 65.04% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformScholar RockOutperform Votes16065.04% Underperform Votes8634.96% Keros TherapeuticsOutperform Votes4770.15% Underperform Votes2029.85% Which has more risk and volatility, SRRK or KROS? Scholar Rock has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Which has better earnings and valuation, SRRK or KROS? Keros Therapeutics has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M70.84-$165.79M-$2.09-14.11Keros Therapeutics$271K8,037.46-$152.99M-$5.13-11.32 Is SRRK or KROS more profitable? Scholar Rock has a net margin of 0.00% compared to Keros Therapeutics' net margin of -62,012.55%. Keros Therapeutics' return on equity of -44.73% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -114.96% -77.22% Keros Therapeutics -62,012.55%-44.73%-41.06% SummaryKeros Therapeutics beats Scholar Rock on 10 of the 19 factors compared between the two stocks. Ad Porter & CompanyBanking failure dead aheadIf you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18B$7.11B$5.36B$8.44BDividend YieldN/A8.77%5.21%4.20%P/E Ratio-11.3216.33140.9817.71Price / Sales8,037.46361.711,510.5793.09Price / CashN/A50.1638.8833.56Price / Book5.235.684.754.60Net Income-$152.99M$151.16M$115.38M$225.57M7 Day Performance-2.54%-1.31%-0.41%-0.02%1 Month Performance-0.03%6.42%3.98%2.07%1 Year Performance103.40%39.09%38.79%33.20% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.3792 of 5 stars$58.04-2.7%$89.11+53.5%+112.8%$2.18B$271,000.00-11.31100Upcoming EarningsShort Interest ↓Analyst RevisionPositive NewsSRRKScholar Rock4.7563 of 5 stars$30.43+1.7%$33.29+9.4%+160.1%$2.39B$33.19M-13.71140Upcoming EarningsPositive NewsDRNADicerna Pharmaceuticals1.0834 of 5 stars$38.22flatN/AN/A$2.99B$164.31M-23.45302SRRASierra OncologyN/A$54.99flatN/AN/A$1.34B$300,000.00-8.12109YMABY-mAbs Therapeutics3.3751 of 5 stars$14.81+2.3%$21.14+42.8%+179.7%$660.08M$86.55M-26.45150Positive NewsAMRNAmarin0.7447 of 5 stars$0.63+8.6%N/A-12.1%$260.16M$306.91M-7.92360News CoverageROIVRoivant Sciences2.9572 of 5 stars$11.84-0.7%$17.39+46.9%+39.4%$8.75B$158.30M2.13860LEGNLegend Biotech1.9903 of 5 stars$45.30+1.3%$82.08+81.2%-32.6%$8.26B$455.99M-58.081,800Analyst ForecastVKTXViking Therapeutics4.1451 of 5 stars$74.52-4.5%$108.60+45.7%+649.0%$8.22BN/A-80.1320Insider SellingAnalyst RevisionITCIIntra-Cellular Therapies4.6039 of 5 stars$76.82+1.3%$96.62+25.8%+84.3%$8.11B$563.44M-88.30560Earnings ReportAnalyst ForecastShort Interest ↓News CoverageRVMDRevolution Medicines3.3065 of 5 stars$47.75+2.9%$56.75+18.8%+175.2%$7.98B$11.58M-13.12443Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Scholar Rock Alternatives Dicerna Pharmaceuticals Alternatives Sierra Oncology Alternatives Y-mAbs Therapeutics Alternatives Amarin Alternatives Roivant Sciences Alternatives Legend Biotech Alternatives Viking Therapeutics Alternatives Intra-Cellular Therapies Alternatives Revolution Medicines Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KROS) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
